With the sequencing of the human genome and the development of new genomic technologies, biomedical discovery has been transformed. The applications of these new approaches are ever-expanding from disease classification, to identification of new targets, to outcome prediction. A logical next step is the integration of genomic approaches into small molecule discovery. This review will focus on the application of genomics to compound discovery, with an emphasis on the hematological malignancies. It will focus on the use of genomic tools to discover cancer targets and the development and application of both cell-based and in silico gene expressionbased approaches to small molecule discovery.
Introduction
The development of new genomic technologies has dramatically altered the scope of cancer-based discovery. With the ease of access to primary patient samples, hematological investigation has been at the forefront of advancing these new approaches. The DNA microarray, a tool enabling the generation of expression data for thousands of genes, is a central new genomic tool. Initially applied to the taxonomy of disease, the applications of gene expression profiling have continued to grow with the ultimate goal now of connecting human disease with potential therapeutics. One approach is to use emerging genomic technologies to identify and validate potential therapeutic targets for cancer. A second is to use gene expression signatures directly in small molecule discovery for cancer therapeutics.
DNA microarrays and taxonomy of hematological malignancy
Despite some skepticism regarding the utility of gene expression profiling, it soon became clear that the DNA microarray would be important in cancer discovery. Beginning in the late 1990s, in a study by Golub et al., 1 it was determined that genome-wide expression patterns, generated with Affymetrix DNA microarrays, could indeed be applied to distinguish acute lymphoblastic leukemia (ALL) from acute myeloblastic leukemia (AML) and could further refine the classification of ALL into B-and T-lineage disease. 1 Although now seemingly simplistic, this pivotal study was among the first to demonstrate that human disease could be classified based exclusively on gene expression. This study also began the difficult task of building computational tools to analyze tens of thousands of data points across a limited number of samples. The next step was to determine if the DNA microarray could be applied to a more fine-grained taxonomy that reflects specific molecular genetic abnormalities. Several years of investigation has yielded a large body of work validating this hypothesis. For example, gene expression studies revealed that mixed-lineage leukemia (MLL)-rearranged ALL is an entity distinct from ALL and AML; 2 that ALL cytogenetic abnormalities (for example, MLL rearrangements, TEL-AML1, E2A-PBX1, hyperdiploidy and BCR-ABL) can be distinguished based on gene expression patterns 3, 4 and that cytogenetic subtypes of AML (for example, PML-RARa, AML1-ETO, CBFb-MYH11 and MLL rearrangements) can be classified solely based on expression signatures. 5, 6 Subsequent studies demonstrated that gene expression patterns in diagnostic samples can be used to identify new classes of disease and predict response to therapy in the acute leukemias and lymphomas independent of known clinical or molecular features. 3, [7] [8] [9] [10] [11] [12] [13] For example, in the AML studies, prognostically relevant novel gene expression clusters were identified within the normal karyotype group. 7, 8 Similarly, gene expression profiling has enabled identification of classifiers to predict induction failure in T-ALL when clinical and cytogenetic features have failed 14, 15 and facilitated identification of PTEN mutations in T-ALL with resistance to Notch1 inhibition. 16 Moreover, quite remarkably, gene expression signatures from ALL diagnostic samples were predictive of the development of treatment-related secondary leukemia. 3 In studies of lymphoma, gene expression profiling has also enabled improved classification, outcome prediction and elucidated new understanding of lymphoma biology. For example, gene expression studies enabled outcome prediction in diffuse large B-cell lymphoma, mantle cell lymphoma and follicular cell lymphoma; [9] [10] [11] [12] [13] identified a similarity between the molecular signature of mediastinal large B-cell lymphoma and Hodgkin's lymphoma; 17 and determined an expression signature distinguishing Burkitt's lymphoma from diffuse large B-cell lymphoma. 18 
Genomic technologies enable target-based drug discovery
In parallel with the genomic revolution, there has been a dramatic shift in the approach to drug discovery for cancer from a focus on nonspecific cytotoxic chemotherapy to a focus on target-based therapies. Historically, cytotoxic therapy discovery has relied on simple, phenotypic cell death assays where small molecule libraries are screened in vitro against a panel of cancer cell lines. In contrast, development of target-based therapeutics focuses on modulation of a single molecular target. Targeted therapy offers several potential advantages over cytotoxic therapy: improved patient selection, rational dosing, predictable side effects and mechanisms of resistance, and the testing of rational combination regimens. Targeted therapy development focuses on the specific alterations of the malignant cell that create distinct molecular or pathway dependencies for cell survival and proliferation. Alterations may be genetic mutations, gene rearrangements, epigenetic modifications (that is, methylation or acetylation derangements), lineage features or other metabolic liabilities. An essential first step in targeted therapy discovery is the credentialing of a putative target to determine if the activity of the target is required for the development and/or maintenance of the malignant state. 19 Emerging technologies, including tissue microarrays, single nucleotide polymorphism (SNP) arrays, expression microarrays and reverse protein arrays are enabling the discovery and validation of cancer relevant drug targets.
Target expression
One basic premise has been to identify genes overexpressed in cancer with the notion that overexpression will equate with increased sensitivity to target inhibition. Although this idea must be considered with caution, because drug resistance can be engendered by target overexpression, 20 ,21 the desire to discover genes 'selectively' expressed in cancer has indeed led to the identification of new therapeutic targets. For example, the identification of FLT-3 as a new target in infants with MLLrearranged leukemia was made based on expression profiling data. When genome-wide profiles of primary patient AML, ALL and MLL-rearranged acute leukemia were compared, the most differentially expressed gene distinguishing MLL-rearranged leukemia from AML and ALL without the MLL rearrangement was FLT-3.
2 Subsequent work revealed FLT-3 mutations in patients with the MLL rearrangement providing further validation of FLT-3 as a rational target for patients with MLLrearranged leukemia. [22] [23] [24] FLT-3, a tyrosine kinase with commercially available small molecule inhibitors, is an attractive receptor for targeted therapy. Several trials have been completed and others are ongoing to evaluate the efficacy of FLT-3 inhibitors for patients with leukemia. [25] [26] [27] [28] [29] [30] Differential expression methods (subtractive hybridization, differential display and serial analysis of gene expression) were among the early methods facilitating studies of expression, [31] [32] [33] but they have largely been replaced by comparative methods using DNA microarrays. In addition, new tools for identifying outlier expression in DNA microarray-generated data have been developed. For example, Cancer Outlier Profile Analysis (COPA) enabled the identification of novel ETS translocations in prostate cancer, suggesting that this method may be particularly robust for finding functionally relevant targets. 34, 35 Such computational tools should be of particular interest for the acute leukemias, where rearrangements of transcription factors are a common finding. One other recent advance in gene expression profiling is the use of gene sets, rather than single genes, to query array-based data. Gene set enrichment analysis (GSEA), for example, has been used to discover up-and downregulated pathway activities when single gene analysis did not prove a fruitful approach to gaining biological insight.
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Genetic alterations
As illustrated by the clinical success of all-trans retinoic acid (ATRA) and imatinib in hematological malignancies, direct genetic alteration leading to target activation, and clinical response to a drug targeting the altered protein, remains perhaps the best evidence for the causal role of a given gene in carcinogenesis. [39] [40] [41] There are several types of genetic alterations, including point mutations, focal amplifications, broad amplifications, focal deletions, broad deletions, loss of heterozygosity and translocations. Genetic alterations that are highly frequent in a given tumor type and are present in the majority of cells are a strong indicator of causality. New genomic approaches, which have accelerated the pace of identification of lesions, include (1) large-scale resequencing projects to identify point mutations; (2) exon microarrays, COPA, pairedend resequencing of BAC clones from a genomic library and single-molecule sequencing to identify chromosomal rearrangements; and (3) methods of DNA copy number analyses, such as array CGH and high-density SNP arrays, to detect amplifications, deletions and loss of heterozygosity.
Limitations to current small molecule library screening approaches
Although genomic technologies have the potential to revolutionize the identification and validation of candidate cancer targets, many challenges still remain in small molecule discovery using target-based screening (Table 1) . First, targetbased screening frequently involves ex cellulo assays that do not fully recapitulate in cellulo complexity. Second, it is only the minority of potential cancer targets that have been considered pharmacologically tractable by the pharmaceutical industry. This is a particular challenge facing the hematological malignancy community with transcription factor abnormalities playing a prominent role in the pathogenesis of acute leukemia. Unlike enzymatic targets, such as kinases, transcription factors are not easily amenable to high-throughput screening assays. It has been difficult to develop assays to identify compounds that interfere with protein-DNA or protein-protein interactions. Alternative approaches to small molecule discovery for these targets are needed. Another significant challenge is that despite new genomic technologies, there are many biological processes for which no target has been identified. In addition to the limitations of target-based screening, phenotype-based screening has its own set of challenges. First, complex phenotypes can be difficult to identify in the context of high-throughput screening. Phenotype assays have generally involved simple state changes such as cell death. Moreover, each assay is specialized, requiring unique reagents and customization. Second, and perhaps most challenging, is the difficulty of identifying the protein target of a validated small molecule hit. In the absence of target identification, compound optimization Table 1 Challenges to traditional small molecule library screening approaches becomes nearly impossible. New genomic approaches, however, should enable alternative small molecule discovery strategies to address many of these challenges.
SPOTLIGHT
Gene expression-based high-throughput screening: platform development
We proposed a potential chemical genomic solution to these small molecule discovery challenges: gene expression-based high-throughput screening (GE-HTS) ( Figure 1) . 42 This generic screening method uses genomic signatures as surrogates for different biological states in a small molecule library screen. First, gene expression signatures of the biological states of interest (that is, 'state A' vs 'state B') are defined using genomewide expression profiling. Next, an assay is developed for the high-throughput, low-cost measurement of the signature. Then, a small molecule library is screened for compounds that induce a change from the 'state A' to the 'state B' signature. Unlike traditional phenotype-based screens, GE-HTS does not require development of specialized assays. The gene expression signature definition, amplification and detection are generic. Furthermore, a priori knowledge of a target is not needed. The expression signature serves as a surrogate for the biological state in question.
In the translation of this concept to a high-throughput assay we faced three competing issues. First, we needed to consider throughput. We envisioned the screening of thousands of molecules in 384-well format. Second, we considered the issue of signature complexity. We hypothesized that screen sensitivity and specificity would increase with increasing complexity of gene signature, a hypothesis that was later born out in data. Moreover, the ability to measure tens to hundreds of genes in a single well would enable screening for multiple phenotypic endpoints in the context of a single screening effort. Finally, we needed to consider the reality of cost. On one extreme was the possibility of conventional cell-based screening directly with DNA microarrays. Although ideal for maximal signature complexity, this implementation was not feasible from either a throughput or cost perspective with each well costing over $350. Likewise, although real-time PCR would enable throughput and meet cost requirements, signature complexity in a single well would be greatly compromised. Hence, we turned to other platform solutions. Our first-generation platform amplified signature genes by multiplexed reverse transcription (RT)-PCR performed on cells grown in 384-well format. To quantify the multiplexed RT-PCR signature we turned to mass spectrometry. Briefly, a single base extension (SBE) reaction was performed on the multiplexed PCR amplicons such that the abundance of extended primer reflects abundance of its cognate PCR product. These small, 5-to 10-plex SBE products were then subjected to matrix-assisted laser desorption time-of-flight mass spectrometry, and the extended fragments were quantified. 42 As new technologies emerged, we developed an improved secondgeneration GE-HTS platform to meet the need for increased complexity of signatures, decreased well-to-well variability and reduced cost. This second-generation platform uses ligationmediated amplification (LMA) with a fluorescent bead-based technology for amplicon detection developed by Luminex. 43 As shown in Figure 2 , the LMA is performed in which molecular barcodes are incorporated into the flanking regions of each amplicon. The amplicons are then detected by Luminex beads each coupled to a capture oligonucleotide complementary to one of the barcodes. The next-generation Luminex technology enables the detection of up to 500 distinct colors. Coupled beads are then read on a flow cytometer where one laser detects the bead color (denoting the identity of the transcript) and a second laser detects the phycoerythrin channel (denoting the transcript's abundance). We have found this method to be highly reproducible (R 2 40.95) compared to Affymetrixgenerated expression data, even for low abundance transcripts. 43 
GE-HTS applied to modulating biological states
AML and differentiation
Our first proof-of-concept experiments applied GE-HTS to the identification of new AML differentiation agents (Figure 3) . 42 To define a myeloid differentiation signature, we performed oligonucleotide microarray-based gene expression profiling of pretreatment bone marrow samples derived from patients with AML, as well as of peripheral blood neutrophils and monocytes derived from normal donors, to identify genes correlated with the neutrophil vs AML or monocotye vs AML distinction. We next screened a compound library consisting of 1739 chemicals, enriched for compounds with known biological activity and for Food and Drug Administration (FDA)-approved drugs. We specifically chose to focus on this collection of molecules to facilitate translation to clinical trial and to enable generation of hypotheses about compound mechanism of action. We examined 13 top-scoring compounds that induced either the neutrophil or monocyte differentiation signature. Repeat experiments with these 13 candidate compounds indicated that 8 Figure 1 High-throughput screening (GE-HTS): a conceptual framework. Biological states of interest can be profiled using genome-wide DNA microarrays and gene expression signatures developed. However, despite this new technology, the identification of new targets directly from gene expression data can be difficult. Instead, GE-HTS bypasses the initial need for target identification and uses the gene expression signatures as surrogates in a small molecule library screen. These small molecules will then be used as tool compounds to probe the pathways/targets responsible for the signature switch and as potential lead compounds for clinical trial development.
SPOTLIGHT
reproducibly triggered portions of the differentiation signature. We next confirmed that the majority induced a broader, genome-wide program of differentiation by using oligonucleotide microarray-based analysis. We also investigated the ability of these chemicals to induce the traditional hallmarks of differentiation, including morphological changes, the reduction of nitro-blue tetrazolium (NBT) and the ability to promote phagocytosis. Importantly, these changes were not only limited to cell lines but were also seen in primary patient AML cells. Among the chemicals confirmed in the pilot screen to induce neutrophil differentiation was DAPH1. DAPH1 was previously reported to inhibit epidermal growth factor receptor (EGFR) kinase activity, suggesting that a receptor tyrosine kinase (EGFR or related) may be a target for differentiation therapy. We therefore extended testing to the previously FDA-approved drug, gefitinib (Iressa), a reported EGFR inhibitor. 44 In HL-60 cells, gefitinib induced differentiation based on morphology, NBT reduction, cell growth inhibition, cell-surface markers and whole-genome patterns of expression. Similar effects were seen in other AML cell lines as well as in the majority of primary AML samples tested. Erlotinib (Tarceva), another FDA-approved EGFR inhibitor, also induced similar effects on cell viability and differentiation in AML. 45, 46 Furthermore, gefitinib, in combination with either ATRA or cytotoxic agents, had enhanced activity on differentiation and viability, respectively. 47, 48 In HL-60 cells and Kasumi-1 cells, there is no expression of EGFR as determined by negative RT-PCR and western blot analysis, suggesting that the differentiation-promoting activity of gefitinib is through a non-EGFR mechanism of action. In addition, there is no expression of ERBB2 based on negative western blot analysis. 44 These preclinical studies exposed a non-EGFR, non-ERBB2 target of gefitinib with potential biological and therapeutic implication in AML. Interestingly, recent reports describe patients with AML responsive to erlotinib, a structurally related EGFR inhibitor, including two complete remissions. 45, 49, 50 
Neuroblastoma and differentiation
In addition to the application of GE-HTS to modulating the differentiation state in AML, we extended GE-HTS to modulating differentiation in neuroblastoma, the most common extracranial pediatric solid tumor. 51 In this work, we used a histone deacetylase (HDAC) inhibitor as an enhancer to screen a small molecule library for compounds inducing neuroblastoma differentiation. To quantify neuroblastoma differentiation, we measured a differentiation signature with the LMA/Luminexbased GE-HTS assay. The top hit identified in this screen was ATRA. Secondary assays confirmed greater neuroblastoma differentiation with the combination of an HDAC inhibitor and retinoid than with either alone, and the combination had synergistic activity on cell viability and apoptosis. Moreover, in a xenograft model of neuroblastoma, the combination-treated animals had the longest survival. This work demonstrated the success of signature-based screening to prioritize compound combinations for testing.
GE-HTS and primary cell screening
Most small molecule library screening has been performed in cell lines because of the difficulty in working directly with primary human material. However, there are many problems that cannot be addressed in cell lines, both in cancer-as well as non-cancer-related screens. For example, representative human cell lines for some diseases, such as myelodysplastic syndrome, do not yet exist. In addition, there is a concern that cell lines do not recapitulate human disease secondary to selection for, or acquisition of, additional genetic hits ex vivo. For these reasons, we would ultimately like to perform GE-HTS screens in primary cancer cells and in primary cancer initiating cells. However, because this is a new concept in small molecule screening, there are many technical issues to address. To determine the feasibility of primary cell screening with GE-HTS we conducted a pilot project to address whether GE-HTS could be used to distinguish primary naive human T cells from primary memory human T cells. We first identified a signature for the naive vs memory states and then adapted this signature to the GE-HTS assay. 52 We demonstrated that the 55-gene signature allows better resolution than any one constituent gene and that the method even in primary cells is precise, easily scaled to higher throughput and well correlated with Affymetrix microarray data across different donors. 53 With this proof-of-concept study successfully completed, one ongoing screening effort is now focused on the application of GE-HTS to identify inducers of differentiation of naive primary T-cell precursors into memory T cells, a state change essential for immune response to acute viral infections.
GE-HTS and modulating intractable targets
Beyond applications to modulating state changes, GE-HTS can, in principle, be applied to modulating protein targets previously considered 'undruggable,' such as transcription factor abnormalities. Abnormalities of transcription factors are a common event in the development of the acute leukemias, particularly translocation rendering a new protein with aberrant transcriptional activity. Some examples of common transcription factor rearrangements include ALL (TEL-AML1, MLL rearrangements, E2A-PBX) and AML (PML-RARa, AML1-ETO, CBFb-MYH11, MLL rearrangements). Although initially not thought to be involved in the development of adult carcinomas, data now suggest that rearrangements of transcription factors in adult solid tumors may be common with recent work identifying ETS rearrangements in the majority of adult prostate tumors. 34, 54, 55 The tumor cell specificity and high frequency of the genetic abnormalities make these oncoproteins attractive targets. However, transcription factors have been considered 'undruggable' because of the difficulty in developing appropriate highthroughput assays to measure alteration of their activity. With the treatment of PML-RARa-rearranged APL with ATRA as one of the rare exceptions, 39 no current therapy directly targets these other transcription factor abnormalities. Alternative approaches to small molecule discovery are needed. When safe and effective delivery methods for new technologies such as RNAi are developed, these approaches should facilitate therapeutic targeting of oncogenic transcription factors. Furthermore, gene expression-based approaches may facilitate the identification of small molecules that modulate these previously 'undruggable' proteins.
To validate the application of GE-HTS to modulating transcription factor abnormalities, we focused on the modulation of EWS-FLI in Ewing sarcoma, a pediatric solid tumor. 56 First, the transcriptional profile of A673 Ewing sarcoma cells in the presence or absence of a short-hairpin RNA directed against the endogenous EWS-FLI transcript was established. 57 Then an EWS-FLI inducible rescue system was profiled. From these two data sets, a signature for EWS-FLI on vs EWS-FLI off was developed. Next, a small molecule library was screened in A673 cells for compounds that induce the EWS-FLI off signature. The top hit from this screen, cytosine arabinoside, decreased EWS-FLI protein levels, inhibited cell growth, induced apoptosis and attenuated transformation in multiple EWS-FLI-positive Ewing sarcoma cell lines. In principle, GE-HTS can be used to identify modulators of any oncoprotein for which a signature of the oncoprotein's activity can be defined. This has particular relevance to the hematological malignancies where transcription factor abnormalities are common somatic lesions in the development of the disease. In fact, efforts are currently underway to apply GE-HTS to modulating such abnormalities as AML1-ETO, MLL rearrangements and mutant Notch1 in acute leukemia. GE-HTS provides an avenue for identifying tool compounds for the study of these genetic lesions and for identifying therapeutic leads. In fact, Avalon Pharmaceuticals is leading an industry-based effort to utilize gene expression fingerprints for drug discovery.
The Connectivity Map: an in silico gene expression-based approach to small molecule discovery A second gene expression-based approach to small molecule discovery might create a compendium of gene expression profiles for in silico compound discovery. The notion of creating
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Genomic approaches to small molecule discovery K Stegmaier a compendium of gene expression profiles for small molecule discovery was first demonstrated feasible by Hughes et al. 58 with the creation of a collection of genome-wide expression data from 276 Saccharomyces cerevisiae deletion mutants, 11 conditional alleles and wild-type S. cerevisiae treated with 13 small molecules. In this study, it was demonstrated that gene expression could be used as a universal language to connect a compound (dyclonine) with a novel protein target (Erg2). This work was extended by Lamb et al. 59 at the Broad Institute of Harvard and MIT with the Connectivity Map (C-Map), an effort to develop a generic solution to connect human disease with the genes that cause them and to drugs that might treat them (Figure 4) . Their end product is a large reference database of genome-wide expression profiling from cultured human cell lines treated under standard conditions with small molecules and a pattern-matching software to enable data mining. In its first public release (Build 1), the C-Map profiled 164 discrete bioactive small molecules in a total of 564 gene expression profiles (453 individual instances defined as one treatment and vehicle pair), across four human cell lines (breast cancer MCF7, acute myeloid leukemia HL-60, prostate cancer PC3 and melanoma SKMEL5) on the Affymetrix high throughput array (HTA) platform. A uniform time point of 6 h was assessed with most compounds profiled at 10 mM. Each treatment instance was defined relative to control cells treated with vehicle and grown in the same plate. The software tool utilized is based on the Kolmogorov-Smirnov statistic and uses a nonparametric, rankbased pattern-matching strategy. 60 This approach begins with a user-defined 'query signature' consisting of genes whose expression is associated with a given condition. For each treatment in the C-Map, the 22 000 genes are rank-ordered based on their differential expression relative to the batch control. The similarity or 'connection' of the query signature to each of the expression profiles in the reference collection is then assessed. If upregulated genes in the query signature appear toward the top of the list and downregulated genes toward the bottom of the list for any compound, then that compound has 'positive connectivity.' If the upregulated query genes appear toward the bottom of the list and the downregulated genes toward the top of the list then the compound has 'negative connectivity.'
C-Map: guiding principles
As described by one of its inventors, Lamb, 61 the C-Map is based on several guiding principles. One primary objective was to centralize in a public reference database the genome-wide effects of all bioactive molecules and genetic perturbations (that is, RNAi and ORFs) profiled in the universal language of gene expression, thereby eliminating redundant efforts among individual investigators and hence wasted time and resources. Furthermore, because of the known operator variability in gene expression profiling data, the centralization and systematization of sample preparation and profiling procedures should reduce program-dependent idiosyncrasies. Here, the development of the Affymetrix HTA platform facilitated the systematization of data collection because it enabled automated amplification, labeling and hybridization of 96 samples with parallel processing, and reduced cost per sample. However, the profiling of potentially thousands of molecules is still an expensive undertaking and compromises must be made. One simply cannot profile all of the estimated 200 cell types, across multiple time points and doses, and all known chemical or genetic perturbagens. Here, in the initial pilot study, the investigators chose to focus on a small number of human cancer cell lines and generally a single treatment duration and dose. What they found, perhaps surprisingly, is that issues of cell context and dose mattered less than might be predicted. For the C-Map to truly succeed in its mission, however, the individual researcher needs to be an empowered user and the database accessible. Here, the solution was to develop a two-part format with internal reference data (genome-wide profiles) generated systematically by the Broad Institute with HTA and the external query data (a gene expression signature of the biological state of interest) identified by the individual investigator-user. Queries can therefore be derived from any gene expression profiling platform and from any tissue depending on the user's preference. The C-Map is available on a publicly accessible website (http://www.broad.mit.edu/cmap) that also includes meta-data, such as perturbagen name, concentration, cell line and batch) and analytical tools. It provides links for each compound to a vendor, to ChemBank (a database for structures and synonyms, http://chembank.broad.mit.edu), 62, 63 and displays the Anatomical Therapeutic Chemical classification assigned by the World Health Organization to drug substances. Moreover, the raw data are freely available for download. The second build of the C-Map (Build 02) now includes 7056 scans, 6100 instances and 1309 discrete small molecules that have been publicly released.
An ultimate principle of the C-Map is that it is actionableFthat is one can generate a hypothesis and then test it with traditional approaches. Two clinically relevant examples provided below demonstrate these principles.
C-Map and the discovery of modulators of glucocorticoid resistance in ALL. The clinical problem of interest in this study was that of glucocorticoid resistance in patients with ALL. Both in vitro and in vivo data confirm that blast resistance to glucocorticoids portends a poor prognosis in patients with ALL yet no drugs had been identified that successfully alter that resistance. [64] [65] [66] Wei et al. 67 developed a gene expression signature for glucocorticoid sensitivity or resistance by whole-genome profiling of 29 pretreatment ALL samples that were determined to be either sensitive or resistant to glucocorticoid-induced apoptosis in vitro. The goal was to identify small molecules that reverse the resistance signature. The investigators used this signature as an in silico C-Map query. The 10 instances of sirolimus (commonly known as rapamycin), the mammalian target of rapamycin inhibitor, were ranked near the top of the C-Map list, a connection beyond that expected by chance alone (Po10 À5 ). This finding led to the testable hypothesis that rapamycin would induce glucocorticoid sensitivity in resistant cells. Subsequent experiments confirmed that rapamycin indeed sensitized resistant ALL cells to the proapoptotic effects of dexamethasone by modulation of the antiapoptotic protein MCL1. These results led to the development of an ongoing clinical trial testing the combination of prednisone and rapamycin in patients with relapsed or refractory ALL. This work highlights two important points. First, the query signature was developed in primary patient ALL blasts, not one of the cell lines used in the C-Map. Second, results were actionable: a hypothesis was generated, tested, validated and led to a clinical study.
Modulating androgen receptor signaling: the interface of GE-HTS and C-Map
In a second example, a study by Hieronymus et al., 68 the interplay between GE-HTS and C-Map is well illustrated. Faced with the difficult challenge of modulating androgen receptor signaling in prostate cancer, the investigators used GE-HTS to identify small molecule inhibitors of an androgen receptor activation signature in the prostate cancer cell line LNCaP. Two of the molecules that emerged were the structurally related natural product triterpenoids, celastrol and gedunin. After validating the activity of these two compounds on androgen receptor signaling, they were faced with the notoriously difficult task of identifying the molecular basis for their activity. They next turned to genome-wide expression profiling of gedunin and celastrol in LNCaP cells and identified an expression signature that was used in a C-Map query. This analysis showed a strong connection between the celastrol/gedunin query signature and four HSP90 inhibitors in the C-Map suggesting the hypothesis that celastrol and gedunin activity was by altering HSP90. This prediction was validated with follow-up studies demonstrating that celastrol and gedunin indeed inhibit HSP90 activity and HSP90 client proteins.
GE-HTS and C-Map: compare and contrast
As illustrated above, the C-Map and GE-HTS are complementary signature-based approaches to small molecule discovery ( Table 2 ). Although C-Map is an in silico small molecule discovery tool, GE-HTS uses a conventional cell-based screening format. Because of the expense of C-Map at approximately $350 per sample and the lack of conventional screening throughput, the number of total molecules, doses and treatment durations is limited. Moreover, discovery cannot be highly dependent on a specific cellular context as only four cell lines have been profiled. However, signature complexity is on a genome-wide scale. In contrast, because GE-HTS uses a conventional cell-based screening format, the screener can tailor the screen to an optimized cell of choice, whether a cell line, or primary cell, and in principle, whole organisms, such as the zebrafish, could be studied. Moreover, the investigator can control time point, dose and library selection, and many more compounds can be profiled because the per-well cost is two orders of magnitude lower than for a C-Map sample. The improved throughput, flexibility in screening parameters and markedly lowered cost are at the expense of signature complexity. However, as the number of genes detectable with Luminex technology continues to increase (from 100 to 500), one can imagine that the lines between GE-HTS and C-Map could become blurred. What if one could reduce genome-wide complexity to 1000 representative genes detectable by a fluorescent bead-based platform? Then, one could afford to profile many more molecules, cell lines, doses and so on in a C-Map context. Moreover, the complexity of signatures detected in a GE-HTS screen would increase dramatically.
In silico screening of public gene expression data Yet another question is whether public gene expression data can be mined more broadly, across institutions and data sets, not exclusively within a controlled C-Map-like systematized collection. Hassane et al. 69 were interested in discovering agents that eradicate leukemia stem cells. Their earlier work had identified parthenolide as a molecule that selectively kills AML stem cells compared to normal hematopoietic cells through inhibition of nuclear factor-kB (NF-kB) and induction of oxidative stress. 70 The investigators hypothesized that a gene expression signature reflecting the treatment of primary AML cells with parthenolide could be used to perform in silico screening of publicly available gene expression data (including the C-Map) for molecules inducing a similar signature. They identified two Table 2 GE-HTS vs C-Map comparison
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GE-HTS C-Map
Cell-based screen In silico screen Screener chooses cell Limited cell lines B$1-2 per well B$350 per sample Up to 500 genes per well B22 000 genes per sample Ten of thousands of compounds B1200 compounds new compounds, celastrol and 4-hydroxy-2-nonenal, that recapitulate the parthenolide signature. As expected, these molecules also ablate AML cells at all levels: bulk, progenitor and stem cell with inhibition of NF-kB and induction of oxidative stress. As in the C-Map studies, this work demonstrated that cell context is not always critical to identify gene expression connections. Here, molecules with potential to modulate AML stem cells were identified despite the fact that AML stem cells had not been profiled in the publicly available data.
Conclusions
Since the discovery of nitrogen mustard as a therapy in the 1940s, incredible progress has been made in the treatment of cancer, particularly for the hematological malignancies. Advances have been made with both multiagent cytotoxic chemotherapy discovered by phenotypic screening (for example, the treatment of pediatric ALL) and the application of newer targeted therapies (for example, imatinib for BCR-ABL-rearranged CML). New and emerging genomic approaches will greatly facilitate target-based screening by enabling methods to more rapidly identify and credential candidate targets. Moreover, genomic technologies facilitate new strategies for small molecule discovery, enabling the modulation of intractable targets, screening in the absence of a priori target knowledge and potentially the prediction of drug toxicity. Although not expected to replace the traditional phenotype-and target-based assays, signature-based screening approaches, such as GE-HTS and C-Map, should play a complementary role in compound discovery. Approaches such as these will ultimately require cross-disciplinary collaborations (that is, cancer biology, molecular genetics, chemical biology, medicinal chemistry, computational biology, computer science and clinical medicine) and the public sharing of data to accelerate achieving the ultimate goal of more effectively treating human disease.
